News
-
-
REGULATED PRESS RELEASE
NFL Biosciences announces the success of its capital increase capped at €3 million
NFL Biosciences successfully completes €3 million capital increase with oversubscription, involving international and French investors; plans Phase 3 clinical trial for smoking cessation drug NFL-101 -
-
PRESS RELEASE
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Curatis Holding AG reveals Corticorelin as active substance of C-PTBE-01, targeting larger patient group for PTBE treatment. Strengthened team with Dr. Kirsty Crame and Dr. Timm Trenktrog. Market opportunity in PTBE surpassing USD 1 billion -
-
PRESS RELEASE
PolyPeptide announces expansion of existing credit facilities
PolyPeptide Group AG secures EUR 40 million additional financing under existing credit facilities, supported by main shareholder Draupnir Holding B.V., enhancing financial flexibility for growth towards doubling revenue by 2028 -
-
-
PRESS RELEASE
Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology
Onco-Innovations appoints Professor Steven Jones as Senior Scientific Advisor to advance precision oncology through AI-powered solutions -
PRESS RELEASE
Cerrado Gold Announces First Quarter Financial Results Release Date and Conference Call
Cerrado Gold Inc. to release Q1 2025 financial results on May 29, 2025, and host conference call to discuss financial performance and outlook. Company overview and projects in Argentina, Portugal, and Canada outlined